Search

Your search keyword '"Henske, Elizabeth P."' showing total 647 results

Search Constraints

Start Over You searched for: Author "Henske, Elizabeth P." Remove constraint Author: "Henske, Elizabeth P."
647 results on '"Henske, Elizabeth P."'

Search Results

1. TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex

2. Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group

4. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma

5. Tumour predisposition and cancer syndromes as models to study gene-environment interactions.

7. Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1

10. The Spectrum of Renal "TFEopathies": Flipping the mTOR Switch in Renal Tumorigenesis.

11. Pathophysiology of Lymphangioleiomyomatosis

12. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

17. Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group

19. Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference

25. The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma

26. Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis.

28. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

30. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

31. Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms

34. Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC).

36. Supplementary Figure 4 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

37. Supplementary Figure 3 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

38. Supplementary Table 1 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

40. Data from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

42. Supplementary Figure 8 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

43. Data from The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch–Nodal Axis

45. Supplementary Figure, Figure Legends, Tables and Material and Methods from The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch–Nodal Axis

46. Supplementary Figure 5 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

47. Supplementary Figure Legend from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

48. Supplementary Figure 2 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

49. Supplementary Figure 7 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

Catalog

Books, media, physical & digital resources